CDC investigators looked at what might cause reinfections during the first wave of the pandemic.
Before the arrival of various variants of COVID-19, such as the Delta variant, reinfection of health care professionals and first responders over a 9-month period was fairly uncommon, according to a study in Clinical Infectious Diseases. Investigators with the Centers for Disease Control and Prevention (CDC) looked at serology surveys and viral testing results of participants from Rhode Island from March 1, 2020, to February 17, 2021, and for New York City participants from March 10, 2020, to December 14, 2020. The rollout of vaccines began December 14, 2020, in both jurisdictions but vaccine data were not used in this study, and symptom data were also unavailable.
“Seropositivity decreased reinfection risk,” the study states. “Lower reinfection risk associated with exposure to a household member with COVID-19 before the serosurvey may reflect subsequently reduced household transmission among members of previously infected households.”
Included in the study were individuals who tested positive for SARS-CoV-2 14 or more days after their first serology test. The CDC investigators defined reinfection as a second positive test 90 or more days after the first positive test.
“The association between serostatus and reinfection was assessed with a proportional hazards model adjusting for demographics, exposures, and virus testing frequency,” the study states.
Of 1572 participants who’d been infected with SARS-CoV-2, 40 (2.5%) were reinfected. Reinfections for seropositive participants was 1.9%; while 8.4% of seronegative participants were reinfected. Most of the reinfections occurred among nursing home residents and corrections personnel in Rhode Island (n=30). They were also tested the most, with a mean testing rate of 30.3 tests as opposed to 4.6 for other Rhode Island and New York City participants.
The greater number of tests in Rhode Island sprung from the CDC mandating routine periodic testing for nursing home residents and staff. The Rhode Island Department of Health conducted frequent testing among prison personnel because of COVID-19 outbreaks in those institutions.
“Although increased testing frequency was mandated in New York skilled nursing facilities, nursing home personnel were not included in the New York City serosurvey,” the study states.
The adjusted hazard ratio (aHR) for reinfection in seropositive versus seronegative persons was 0.41 (95% CI 0.20, 0.81),” the study states. “Exposure to a household member with COVID-19 before the serosurvey was also protective (aHR 0.34, 95% CI 0.13, 0.89).”
Individuals who reported exposure to a household member with COVID-19 prior to the serology survey were less likely to be reinfected. Reinfection was not associated with other risk factors such as underlying health conditions.
“Studies of health care personnel have found that community transmission was a strong risk factor for initial infection,” the study states. “Persons initially infected in their households may have a lower risk of subsequent household infection if household members also developed immunity.”
Comprehensive Strategies in Wound Care: Insights From Madhavi Ponnapalli, MD
November 22nd 2024Madhavi Ponnapalli, MD, discusses effective wound care strategies, including debridement techniques, offloading modalities, appropriate dressing selection, compression therapy, and nutritional needs for optimal healing outcomes.
The Leapfrog Group and the Positive Effect on Hospital Hand Hygiene
November 21st 2024The Leapfrog Group enhances hospital safety by publicizing hand hygiene performance, improving patient safety outcomes, and significantly reducing health care-associated infections through transparent standards and monitoring initiatives.
Managing Multimorbidity and Polypharmacy in HIV: Insights From Michelle S. Cespedes, MD, MS
November 20th 2024Michelle S. Cespedes, MD, MS, discusses the challenges of managing multimorbidity and polypharmacy in HIV treatment, emphasizing patient education, evolving guidelines, and real-world insights from the REPRIEVE study.
Longhorn Vaccines and Diagnostics to Showcase Breakthrough Vaccine Data at IDWeek 2024
November 19th 2024Longhorn Vaccines and Diagnostics revealed promising data on universal influenza vaccine LHNVD-110 and AMR sepsis vaccine LHNVD-303 at IDWeek 2024, addressing critical global health challenges.